IL6 and neoplasm: Dysbiosis-associated ligands (e.g., LPS, flagellin) activate TLRs to drive NF-κB and IL-6/STAT3 signaling, thereby amplifying tumor fitness, blunting antitumor immunity, altering antimicrobial-peptide programs, and increasing epithelial permeability [91,92].